CTLA4 and cancer: The development of immunotherapeutics and immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programed death 1 (PD-1) molecules are being studied in clinical trials for the treatment of different types of cancer [116].